Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies
On demand

Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies

Meeting the need for innovation in both upstream and downstream AAV viral vector bioprocess technology is a crucial step towards ensuring the continued emergence of the commercial gene therapy sector. A second and closely related one is evolving the analytics required to ensure consistent, robust and cost-effective manufacture. In this webinar, Thermo Fisher Scientific describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.

Attendees find out:

  • How innovation in upstream technology will deliver process robustness and titer enhancement
  • How to optimize and effectively scale up downstream bioprocess workflows in order to capitalize on increased upstream yields
  • What is the latest thinking and innovation in developing the analytics needed to improve both the quality and efficiency of viral vector manufacture for gene therapy
  • New regulatory paradigm for accelerated cell and gene therapy product development.
  • Key points of future focus for further investment and collaboration


Brandon Pence
Brandon Pence
Vice President & General Manager, Pharma Purification & Analytics at Thermo Fisher Scientific

Brandon Pence has more than 20 years of experience in the life sciences industry leading teams in R&D, product management, marketing and business strategy. Brandon began his career at Thermo Fisher Scientific in R&D and spent more than 15 years in a variety of technical and business management roles with increasing degrees of responsibility.

Following four years with GE Healthcare leading their bioprocessing marketing and strategy teams at their headquarters in Sweden, Brandon returned to Thermo Fisher as the Vice President of Market Development and Strategy for the BioProduction division. In 2019, Brandon took on the role of VP and General Manager of the Purification and Pharma Analytics business. Brandon is a graduate of Utah State University where he studied Cell Biology. He and his family currently reside in Utah.

Richard Snyder
Richard Snyder
CSO at Thermo Fisher Scientific

Richard O. Snyder, PhD is the Vice President for Science and Technology, Pharma Services, Viral Vector Services at Thermo Fisher Scientific. Dr. Snyder has been investigating virus biology, vector development, cGMP vector manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 33 years, and was a member of teams who developed novel viral vector-based human gene therapies.

Dr. Snyder was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in Biology from Washington University in St. Louis.

Kate Torchilin
Kate Torchilin
Vice President and General Manager, Cell Culture and Cell Therapy at Thermo Fisher Scientific
Dr. Kate Torchilin is Vice President & General Manager of Cell Culture & Cell Therapy, BioProduction at Thermo Fisher Scientific. Kate previously was responsible for Purification & Pharma Analytics, BioProduction at Thermo Fisher Scientific. Earlier in her career, Kate held various executive and management positions at Novaseek Research, Alere, Biocell Center Corp, Thermo Fisher Scientific and Beth Israel Deaconess Medical Center, Harvard Medical School teaching hospital. Kate has an MBA from Harvard Business School, a PhD in Biochemistry from Tufts University and her BS in Chemistry from Moscow State University, Russia.